Onyx Biotec

Onyx Biotec Limited - IPO

SME

Onyx Biotec Stock Price

51.90 A2ZIPO
1.90 (3.80%)
12 Jun, 2025 02:47:29 PM | All Prices in ₹
Previous Close
50.00
Open
52.45
High
52.45
Low
51.90
Exchange
NSE
52 week High (02 Jan 2025)
97.45
52 week Low (30 May 2025)
45.00
Upper Price Band
52.50
Lower Price Band
47.50
Price Band
5.00%
All Prices in ₹
Previous Close
-
Open
-
High
-
Low
-
Exchange
BSE
52 week High
-
52 week Low
-
Upper Price Band
-
Lower Price Band
-
Price Band
-

Onyx Biotec IPO Details

Open Date
13 Nov 2024
Close Date
18 Nov 2024
Listing Date
22 Nov 2024
Issue Price
₹58 - ₹61
Face Value
₹10 per share
Lot Size
2000
GMP
₹5 (8.2%)
Issue Type
IPO
Listing On
NSE
Type
Book Built Issue
Share holding pre issue
13322200
Share holding post issue
18132200
Total Issue Size
48,10,000 shares (aggregating up to ₹29.34 Cr)
Fresh Issue
48,10,000 shares (aggregating up to ₹29.34 Cr)
Offer for Sale
-

Onyx Biotec IPO Subscription

Onyx Biotec IPO Application Wise Breakup

Onyx Biotec IPO Dates

  • 13 Nov 2024
    Opening dateOPD
  • 18 Nov 2024
    Closing dateCOD
  • 19 Nov 2024
    Basis of AllotmentBOA
  • 21 Nov 2024
    Initiation of RefundsIOR
  • 21 Nov 2024
    Credit of SharesCOS
  • 22 Nov 2024
    Listing dateLID

Onyx Biotec IPO Lot Size

ApplicationLotsSharesAmount
Retain Minimum12000₹122,000
Retain Maximum12000₹122,000
HNI Minimum24000₹244,000

Onyx Biotec IPO Reservation

Promoter Holding

Pre Issue:88.60%
Post Issue:-
Promoter Names:
Sanjay Jain, Naresh Kumar, Fateh Pal Singh

Onyx Biotec IPO Valuations

EPS Pre IPO:2.28
EPS Post IPO:4.33
P/E Pre IPO:26.81
P/E Post IPO:14.1

Onyx Biotec Limited Financial Information

Onyx Biotec Limited's revenue increased by 35.99% and profit after tax (PAT) rose by 64.35% between the financial year ending with March 31, 2024 and March 31, 2023.

Period Ended31 May 202431 Mar 202431 Mar 202331 Mar 2022
Assets7,476.577,413.585,872.363,683.84
Revenue1,054.115,387.433,961.654,498.09
Profit After Tax130.77303.16184.46335.29
Net Worth2,618.642,487.871,820.161,637.59
Reserves and Surplus1,286.421,155.651,230.001,047.43
Total Borrowing3,156.143,078.042,922.831,224.39
Amount in ₹ Lakhs

About Onyx Biotec IPO

Incorporated in May 2005, Onyx Biotec Limited is a pharmaceutical company providing sterile water for injections. The company currently manufactures Sterile Water for Injections and serves as a pharmaceutical contract manufacturer, offering a comprehensive range of Dry Powder Injections and Dry Syrups for both the Indian and overseas markets.

The company has two manufacturing units in Solan, Himachal Pradesh. Unit I has a daily production capacity of 638,889 units of Sterile Water for Injections, while Unit II produces 40,000 units of dry powder injections and 26,667 units of dry syrup per day in a single shift.

The company clientele includes Hetero Healthcare Limited, Mankind Pharma Limited, Sun Pharmaceutical Industries Limited, Aristo Pharmaceuticals Private Limited, Macleods Pharmaceuticals Limited, Mapra Laboratories Private Limited, Axa Parenterals Limited, FDC Limited, Zuventus Healthcare Limited, Akums Drugs and Pharmaceuticals Limited, Reliance Life Sciences Limited, among others.

As of May 31, 2024, the company had a client base of more than 100 Indian and multinational pharmaceutical companies.

The company has received certificates for the management system, ISO 9001:2015, and ISO 14001:2015 from ROHS Certification Private Limited.

As of July 31, 2024, the company has 175 employees across various departments.

Strength Of Onyx Biotec IPO

1. One of the prominent contract manufacturers in sterile manufacturing.

2. Quality Assurance and Quality Control of our products.

3. Strong, cordial & long-term relationship with our Marque Clientele.

4. Cost effective production and timely fulfilment of orders.

5. Well experienced management team with proven project management and implementation skills.

Risk Of Onyx Biotec IPO

1. Its manufacturing units are concentrated in Solan, Himachal Pradesh, and the company is exposed to risks originating from economic, regulatory, political and other changes in this region, including natural disasters, which could adversely affect its business, results of operations and financial condition.

2. Any slowdown or shutdown in its manufacturing operations could have an adverse effect on its business, results of operations, financial condition and cash flows.

3. Any manufacturing or quality control concerns or its inability to deliver products on a timely basis, or at all, could result in the cancellation of purchase orders, breaches of relevant agreements, and termination of agreements by its clients and distributors, which could have an adverse effect on its business, results of operations, financial condition and cash flows.

4. Its manufacturing units are subject to periodic inspections and audits by regulatory authorities and clients. The company may be subject to regulatory action which may damage its reputation leading to an adverse effect on its business, results of operations, financial condition and cash flows.

5. The company relies on domestic and international third-party suppliers for the supply of raw materials and any delay, interruption or reduction in such supply could adversely affect its business, results of operations, financial condition and cash flows.

6. Its business is dependent on sale of products to a limited number of clients for a significant portion of its revenues. The loss of one or more such clients or the deterioration of their financial condition or prospects could adversely affect its business, results of operations and financial condition.

7. The Company is reliant on the demand from the pharmaceutical industry. Any downturn in the pharmaceutical industry or an inability to increase or effectively manage its sales could have an adverse impact on the Company's business and results of operations.

8. The commercial success of its products depends to a large extent on the success of the products of its customers. If the demand for the products of the company's customers declines, it could have a material adverse effect on its business, financial condition and results of operations.

9. Its may faces several risks associated with the proposed expansion of the company's manufacturing facilities, which could hamper its growth, prospects, cash flows and business and financial condition.

10. Its cannot assure you that the proposed expansion of the company's manufacturing units will become operational as scheduled, or at all, or operates as efficiently as planned. If the company is unable to commission its new facilities in a timely manner or without cost overruns, it may adversely affect its business, results of operations and financial condition.

Objectives Onyx Biotec IPO

  1. Upgradation of existing manufacturing Unit I to manufacture large volume parentals for intravenous use;
  2. Setting up a high-speed cartooning packaging line at existing manufacturing Unit II for Dry Powder Injections;
  3. Prepayment or repayment of all or a portion of certain loans availed by the Company; and
  4. General Corporate Purposes.

Company Contact Details

Onyx Biotec Limited
Bir Plassi Near Sainimajraropar,
Nalagarh Road
District Solan – 174101,
Phone: +91 172 265 6384
Email: generalinfo@onyxbiotec.com
Website: http://www.onyxbiotec.com/

Registrar Contact Details

Name: Mas Services Limited
Phone: +91-11-26387281, +91-11-26387282

Lead Mangers

  1. Horizon Management Private Limited

Market Maker

  1. Giriraj Stock Broking

Comments